Bevacizumab and hereditary haemorrhagic telangiectasia

被引:8
作者
Cruikshank, Ross P. [1 ]
Chern, Boris W. [1 ]
机构
[1] Redcliffe Hosp, Brisbane, Qld, Australia
关键词
D O I
10.5694/j.1326-5377.2011.tb02989.x
中图分类号
R5 [内科学];
学科分类号
100201 [内科学];
摘要
引用
收藏
页码:324 / 325
页数:2
相关论文
共 5 条
[1]
Hereditary haemorrhagic telangiectasia: current views on genetics and mechanisms of disease [J].
Abdalla, SA ;
Letarte, M .
JOURNAL OF MEDICAL GENETICS, 2006, 43 (02) :97-110
[2]
Bevacizumab in Hereditary Hemorrhagic Telangiectasia [J].
Bose, Prithviraj ;
Holter, Jennifer L. ;
Selby, George B. .
NEW ENGLAND JOURNAL OF MEDICINE, 2009, 360 (20) :2143-2144
[3]
Bevacizumab reverses need for liver transplantation in hereditary hemorrhagic telangiectasia [J].
Mitchell, Andrew ;
Adams, Leon A. ;
Mac Uillan, Gerry ;
Tibballs, Jon ;
Driesen, Rohan Vanden ;
Delriviere, Luc .
LIVER TRANSPLANTATION, 2008, 14 (02) :210-213
[4]
Oosting S, 2009, NEW ENGL J MED, V361, P931, DOI 10.1056/NEJMc091271
[5]
Sadick H, 2005, HAEMATOLOGICA, V90, P818